RxDoctor Payments Data

Christi Cowell

Family · Cincinnati, OHNPI 1386315646

Payments from drug & device makers

$1,080in general payments, 2019–2025

Across 46 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$343
  • AbbVie$151
  • Lilly USA, LLC$121
  • Insulet Corporation$113
  • Bayer$46
  • Corcept Therapeutics$37
  • plus $269 from 13 others

What the payments were for

  • Food & beverage$98391%
  • Education$979%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,080 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$24,560
Medicare patients
171
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide54$75,487
OzempicSemaglutide58$72,181
JardianceEmpagliflozin43$56,968
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt26$48,442
Synjardy XrEmpagliflozin/Metformin Hcl33$38,304
Tresiba Flextouch U-200Insulin Degludec21$36,278
MounjaroTirzepatide16$26,155
JanuviaSitagliptin Phosphate24$24,692
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$20,275
EliquisApixaban17$17,916
RybelsusSemaglutide12$16,554
Tresiba Flextouch U-100Insulin Degludec24$15,234
InvokanaCanagliflozin14$13,960
FarxigaDapagliflozin Propanediol14$13,746
NovologInsulin Aspart17$7,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$121$111,183117 claims
Novo NordiskOzempic, Rybelsus, Novolog$343$96,56287 claims
MerckJanuvia$17$24,69224 claims
PfizerEliquis$21$17,91617 claims
Johnson & JohnsonInvokana$15$13,96014 claims
BayerKerendia$46$7,63412 claims
Sanofi-aventis U.S. LLCLantus$16$1,70411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →